Pharmaceutical Commerce - May/June 2013 - (Page 3)
Should personalized medicine imply compromised patient safety?
Continuing problems with compounding pharmacies muddle biopharma’s
To a surprising extent, pharma manufacturers have been on the sidelines as the compounding-pharmacy crisis, which began several months
ago at a now-shuttered pharmacy, New England Compounding Center (NECC), plays out. In early April, the Centers for Disease Control, which
has been monitoring the outbreak and guiding healthcare providers’ response, documented 53 deaths and 733 injuries.
The Pew Charitable Trusts, which funds an ongoing medical safety policy effort, counted 75 deaths and over 1,000 injuries dating back to
2001 from compounded products. Pew sponsored a “stakeholder summit” earlier this year, and published a proceedings in April, just as new
Congressional hearings were about to commence. Pharma trade associations, including PhRMA, BIO and GPhA, were neither participants nor
observers at the summit; nor have there been public statements from these organizations about the ongoing outbreak.
As has been explained repeatedly by FDA and others since the crisis surfaced, some compounding pharmacies operate in a nether world
between being a “manufacturer” (obliged to conduct clinical trials and seek FDA approval for newly formulated products) and a traditional
“pharmacy” (where compounding has been a practice—for individual dosages for specific patients—since the pre-industrial era). FDA has some
regulatory oversight, but has also been hampered by court rulings brought by compounding pharmacy organizations that reject that oversight.
What has evolved over the past 20 years or so is a business—estimated to be worth as much as $9 billion annually—of producing compounded
products in bulk, and to have them on hospital pharmacy shelves or in clinics, ready for use by patients. Most recently, when FDA initiated a
“priority inspection” of compounding pharmacies between February and April, 28 of 29 facilities received Form 483 warning letters (and the only
one that did not was found not to be producing compounded sterile products). During this campaign—and despite the publicity surrounding the
NECC outbreak—four of the facilities objected to allowing FDA inspectors onsite, and two required FDA to obtain administrative warrants, and
to show up with US marshals in tow.
There are several interrelated issues to be worked out. USP Chapter <797>, the guiding document for safe compounding, is in force only
in some states. FDA is seeking new legislative authority, while a trade group representing compounding pharmacies wants to keep regulatory
oversight at the state level, while simultaneously bemoaning the lack of necessary resources at state boards of pharmacy. (In a recent Bloomberg
News article,* a lawyer representing compounding pharmacies is quoted for the following howler: “If a pharmacy waits to do everything in
compliance then patients won’t get treatment.” (Imagine a pharma manufacturer making that defense!)
Here’s where biopharma’s interests come into play: while many compounded products are generics, some are not: one recent recall involved
Roche’s Avastin (bevacizumab) being formulated for use in macular degeneration, but causing eye infections and blindness (Roche makes a
similar product, Lucentis, expressly for macular degeneration, but it costs more. So patients are knowingly or unknowingly trading cost for
safety.) Hospitals seek (or produce) compounded products, in some cases, simply because manufacturers do not offer them in forms suitable for
patient use (is this an “unmet medical need?”) Finally, there is an overlap between compounded products and ongoing drug shortages (see p. 28);
if the drug were available, hospitals and clinics wouldn’t be seeking alternative sources.
In a follow-up to the Pew meeting, Cynthia Reilly, a director at American Soc. of Health-System Pharmacists, stated, “In an era of personalized
medicine based on genomic information or patient weight, we’re moving away from standardized drugs, and that will drive the future need for
compounding.” Such drugs have already started to appear. Will the biopharma industry exert control over how these drugs and related therapies
are dispensed, or will they cede that to pharmacists and clinicians? Will the general public make these fine distinctions between manufacturersourced products, and those that have been compounded, or tar everyone with the same brush?
Required reading from Pharmaceutical Commerce
Value Chain eNewsletter – published twice monthly • Cold Chain eNewsletter – published monthly
The latest biopharma commercial operations and cold chain management news.
Visit our new website...
May | June 2013 Visit our website at www.PharmaceuticalCommerce.com 3
Table of Contents for the Digital Edition of Pharmaceutical Commerce - May/June 2013
Pharmaceutical Commerce - May/June 2013
Table of Contents
Brand Marketing & Communications
Supply Chain/ Logistics
Manufacturing & Packaging
Legal & Regulatory
Meetings and Editorial Index
Pharmaceutical Commerce - May/June 2013